AzTrials
AzTrials

Intracerebral HemorrhageREACHNCT04189471

Improving Outcomes for Patients With Life-Threatening Neurologic Illness

An observational study of Intracerebral Hemorrhage and Subarachnoid Hemorrhage, run by University of Maryland, Baltimore at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Background: While the intensive care of patients with life-threatening brain illnesses has advanced tremendously, a large number of therapies are still without proper scientific support. This can be partly explained by the fact that mechanisms of initial brain injury are still not well understood. Read more about this study

Who is it for?
Ages 18 years and older
How many people
5,000 participants
Where
1 siteUnited States
Study dates
8 Sep 2014to 1 Jan 2034
How long will I take part?
12 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: Patients in University of Maryland Medical Center's Neurocritical Care Unit with potentially life-threatening neurological illness aged 18 and older.

Who may be able to join

  • clinical diagnosis of potentially life-threatening neurological illness
  • admitted to Neuro ICU within 14 days of initial injury

Who cannot join

  • known pre-existing neurological deficits related to a developmental disorder
  • prior severe stroke
  • prior severe dementia
  • prior severe head injury
  • prisoners

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Mayurapriyan Somalinga contact

4103284515

msomalinga@som.umaryland.edu

United States1 site, 1 recruiting
  • University of Maryland Medical Center

    Baltimore, Maryland, 21201

    Gunjan Parikh, M.D., 410-328-4515, gparikh@som.umaryland.edu

    Mayurapriyan Somalinga, 4103284515, msomalinga@som.umaryland.edu

    Recruiting

Other trials in United States

About this study

Official title: Recovery After Cerebral Hemorrhage--Improving Outcomes for Patients With Life-Threatening Neurologic Illness

Background:

While the intensive care of patients with life-threatening brain illnesses has advanced tremendously, a large number of therapies are still without proper scientific support.

Read more

This can be partly explained by the fact that mechanisms of initial brain injury are still not well understood. Why additional neurological injury occurs during a patient's stay in the NeuroCritical Care Unit (NCCU) despite current best, evidence-based clinical practices, is also not well understood. However, over the past decade, better tools have become available to measure and monitor the impact of our clinical care on the rapidly changing physiology and chemistry of the injured brain. Some of these tools are CT, MRI, ultrasound, and catheter-based technology measuring blood flow and metabolism. These tools have enabled earlier detection of injury and complications and newer therapeutic strategies.

Purpose:

Examine disease pathways common to all brain injuries seen in the University of Maryland's 22-bed NCCU. Life-threatening neurological illnesses cared for in the NCCU include massive stroke, bleeding in and around the brain (subarachnoid hemorrhage, intracerebral hemorrhage, subdural hemorrhage, intraventricular hemorrhage), brain tumors, difficult to control seizures, neurologic infections, nerve and muscle diseases (such as myasthenia gravis or Guillain-Barre Syndrome), and spinal cord disorders among others. Many NCCU patients are comatose or paralyzed and may suffer injuries in other parts of the body as well.

This effort will require the creation of a robust clinical database for the capture of data including patient characteristics (age, sex), clinical characteristics, medical treatments, surgical interventions, physiological data (such as vital signs, cerebral blood flow, intracranial pressure, cerebral oximetry, etc), laboratory data, and standard-of-care diagnostic studies such as electroencephalography (EEG), ultrasound, CT, MRI, and angiograms. Similar databases exist at other major centers for neurocritical care and have been instrumental to the identification of characteristics both predictive of and associated with outcomes of patients long after their stay in the NCCU.

In addition, the samples collected will be included in the University of Maryland Medicine (UMM) Biorepository which is a shared resource to enable biomedical research by University of Maryland faculty.

Read the detailed description

The objective of the proposed minimal-risk, non-interventional retrospective (January 2012 onwards) as well as prospective, cross-sectional observational study (i.e., NCCU Research Repository) is to better understand the common pathophysiological pathways of life-threatening neurological illnesses, examine how systemic complications (e.g., fever, hyperglycemia, undernutrition, and infections) and our standard-of care management of them may exacerbate brain injury, and determine the impact of injury and intervention on functionally-relevant outcomes.

A systematically collected cohort may have an especially important role in the NCCU where RCTs are difficult to implement or may lack generalizability, and wherein there are pitfalls in research derived solely from administrative databases. This relational database will capture all patients admitted to University of Maryland's dedicated 22-bed adult NCCU. The investigators will not initially collect all potentially relevant fields unique to specific diagnoses. However, future disease-specific studies will allow the addition of data fields in this flexible database environment. This approach will include the tiered acquisition of patient characteristics (age, sex), clinical characteristics, standard-of-care medical treatments and surgical interventions, physiological data (such as vital signs, cerebral blood flow, intracranial pressure, cerebral oximetry etc), laboratory data, and diagnostic studies--particularly neurophysiology, neuropathology, and neuroimaging. Some data elements are inherently less reliable when abstracted from the electronic medical record (e.g., a more detailed social history, establishing premorbid functional status, and independent confirmation of past medical history), and will require an informed consent process to allow the research team to approach subjects or their surrogates.

Similar databases exist at other centers for neurocritical care and have been central to the identification of characteristics, both predictive and associative, of patient outcomes. Done properly, this repository can facilitate many NCCU priorities including hypothesis generating, determining feasibility of single-site trials or involvement in multi-center trials, multimodal monitoring, biomarker research, quality improvement, and resident education.

All data will be collected from the patient medical record, patient bedside monitors, radiology PACS, and laboratory systems. The collection of data will not affect nor delay patient treatment at any instance.

Potential subjects will include patients admitted to University of Maryland's 22-bed NCCU for treatment of a life-threatening neurological illness. All patients 18 years of age and older will be eligible for participation in the study.

At the time study personnel approach the patient or the patient's surrogate to discuss the study, they will be provided with three options: (a) Full Consent, (b) Partial Refusal, or (c) Complete Refusal.

Subject's medical treatment will conform to existing clinical management protocols including routine ICU care. Standard ICU protocols call for assessments of mental status several times a day. The investigators would like to prospectively record the results of these exams in a rigorous, standardized manner. The investigators will attempt to correlate these assessments with clinical events and outcome. In addition to standard clinical treatment, details of each subject's hospitalization, demographic profile, past medical history, family history will be obtained by questionnaire and chart review. At discharge or 2 weeks after admission, a brief examination and mental status test will be performed. The subject and a family member or caregiver may also be asked to return for follow up evaluations 3 and 12 months after initial brain or spinal cord injury, in order to evaluate their longterm neurological status, disability, emotional status, cognitive functioning, and overall quality of life. These interviews may be conducted in person and will take approximately one hour each. For those patients unable to return in person, a shorter telephone interview will be conducted. Outcome measures may include the Glasgow Outcome Scale (GOS), the extended Glasgow Outcome Scale (eGOS), Modified Rankin Scale, Lawton Activities of Daily Living Index, Barthel Index, Sickness Impact Profile (SIP), NIH Stroke Scale, psychosocial assessments, memory and cognitive neuropsychometric tests (e.g. the Montreal Cognitive Assessment-MoCA).

Variables recorded during hospitalization will be examined for statistical correlation with neuropsychometric test results. Candidate pathophysiologic variables with independent predictive value for cognitive dysfunction, (e.g., including severity of illness upon admission, hydrocephalus, ischemia from vasospasm, and laboratory test results) will be identified using Pearson correlation and forward stepwise logistic regression. Relationships between acute pathology (e.g., lesions on neuroimaging or malignant electrical patterns on electroencephalography) and dysfunction within various cognitive domains (memory, attention, visuospatial ability, language) will be examined using contingency tables, Pearson correlation, linear regression, and the Wilcoxon signed rank test. If necessary, multivariate models will be used to confirm that significant independent relationships exist.

Blood samples will be analyzed to identify the factors causing secondary brain injury (e.g., the narrowing of the blood vessels (vasospasm) after initial hemorrhage).

For patients requiring an External Ventricular Drain (EVD) as part of their medical treatment, the cerebrospinal fluid (CSF) is drained into a collection bag, the amount of drainage recorded and the CSF discarded. The investigators may collect a 1 cc sample of the CSF daily prior to discard until it is medically warranted to remove the EVD or 14 days whichever comes first. NO EVD will be placed for the purposes of clinical research.

Keywords
hemorrhage, intracerebral hemorrhage, SAH, Nontraumatic Haemorrhage, ICH, subarachnoid hemorrhage, status epilepticus
Medical subject headings
Cerebral Hemorrhage, Subarachnoid Hemorrhage, Status Epilepticus, Hemorrhage

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of participants who score great than 60 on the Barthel Index

    The Barthel scale is an ordinal scale used to measure performance in activities of daily living. Scores range from 0 to 100. A higher score signifies better outcomes, more independent functionality.

    Measured: 3 month

  2. Number of participants who score great than 26 on the Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment was developed as a quick screening tool for neurological function. It assesses the domains of attention and concentration, executive function, memory, language, visuoconstructional skills, conceptual thinking, calculation, and orientation. The MoCA has been tested extensively for use in a variety of disorders affecting cognition such as HIV, Huntington's chorea, Multiple Sclerosis, Parkinson's disease, stroke, vascular dementia, and substance abuse in addition to the wellness of older adults. The MoCA has been tested in ages ranging from as young as 49 in two reports to old-old (85+) with a variety of education levels. The total possible score is 30 points with a score of 26 or more considered normal.

    Measured: 3 month

  3. Number of participants who score 1 or less on the Modified Rankin Scale

    The Modified Rankin Scale (mRS) measures degree of disability/dependence after a stroke. Scores range from 0 to 6. A lower score signifies better outcomes, more independent functionality.

    Measured: 3 month

  4. Number of participants who have experienced adverse events

    Medical history from hospital discharge to three months will help researchers learn of any adverse events or other medical complications.

    Measured: 3 month

  5. Number of participants who score great than 75 on the EuroQOL

    EQ-5D is a standardised measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D questionnaire also includes a Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).

    Measured: 3 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Dec 2019
  2. Study start8 Sep 2014
  3. Primary completion1 Jan 2034 (estimated)
  4. Study completion1 Jan 2034 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
5,000 participants (estimated)
Target duration
12 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT04189471
Sponsor's protocol ID
HP-00056063
Acronym
REACH
Status last verified
Jun 2026
First submitted
30 Jul 2019
Last updated
2 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Zimmerman W, Pergakis M, Ahmad G, Morris NA, Podell J, Chang WT, Motta M, Chen H, Jindal G, Bodanapally U, Marc Simard J, Badjatia N, Parikh GY. Iodine-Based Dual-Energy Computed Tomography After Mechanical Thrombectomy Predicts Secondary Neurologic Decline from Cerebral Edema After Severe Stroke. Neurocrit Care. 2025 Jun;42(3):804-816. doi: 10.1007/s12028-024-02137-5. Epub 2024 Oct 24.

    PubMed 39448427

Questions about this trial

What is this clinical trial studying?

An observational study of Intracerebral Hemorrhage and Subarachnoid Hemorrhage, run by University of Maryland, Baltimore at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Gunjan Parikh (4103284515, gparikh@som.umaryland.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of participants who score great than 60 on the Barthel Index (time frame: 3 month). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04189471, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in